With 0.94 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.61 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $26.895 whereas the lowest price it dropped to was $25.91. The 52-week range on AKRO shows that it touched its highest point at $37.00 and its lowest point at $15.32 during that stretch. It currently has a 1-year price target of $48.90. Beta for the stock currently stands at -0.19.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKRO was down-trending over the past week, with a drop of -5.97%, but this was down by -15.91% over a month. Three-month performance dropped to -7.07% while six-month performance rose 9.00%. The stock gained 8.41% in the past year, while it has lost -5.97% so far this year. A look at the trailing 12-month EPS for AKRO yields -3.75 with Next year EPS estimates of -4.74. For the next quarter, that number is -1.16. This implies an EPS growth rate of -34.94% for this year and -21.58% for next year.
Float and Shares Shorts:
At present, 69.61 million AKRO shares are outstanding with a float of 58.30 million shares on hand for trading. On 2024-12-13, short shares totaled 3.3 million, which was 473.00000000000006 higher than short shares on 1731628800. In addition to Dr. Andrew Cheng M.D., Ph.D. as the firm’s President, CEO & Director, Dr. Jonathan M. Young J.D., Ph.D. serves as its Co-Founder, Executive VP, COO & Secretary.
Institutional Ownership:
Through their ownership of 1.05382 of AKRO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AKRO reported revenue of $0.0 and operating income of -$81703000.0. The EBITDA in the recently reported quarter was -$71458000.0 and diluted EPS was -$1.05.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKRO since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AKRO analysts setting a high price target of 65.0 and a low target of 35.0, the average target price over the next 12 months is 48.27273. Based on these targets, AKRO could surge 148.47% to reach the target high and rise by 33.79% to reach the target low. Reaching the average price target will result in a growth of 84.53% from current levels.
Analysts have provided yearly estimates in a range of -$3.62401 being high and -$4.20503 being low. For AKRO, this leads to a yearly average estimate of -$3.89975.
